Eswatini vs Myanmar: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Eswatini
1.2%
in 2024
Myanmar
1.3%
in 2024
Eswatini rank
25th
Myanmar rank
24th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Eswatini
- Myanmar
How they compare
Myanmar currently reports 1.3% against 1.2% in Eswatini, a difference of 0.1%.
That makes Myanmar's figure about 1.1 times Eswatini's.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was Myanmar ahead.
Eswatini ranks 25th and Myanmar ranks 24th of 215 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eswatini | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.5% | 1.3% | 0.2% | Eswatini |
| 2020s | 1.4% | 1.1% | 0.3% | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Eswatini or Myanmar?
- Myanmar, at 1.3% against 1.2% in Eswatini as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Eswatini and Myanmar?
- 0.1%, with Myanmar ahead.
- How many years of comparable data are there for Eswatini and Myanmar?
- 10 years are reported by both, from 2015 to 2024.
- How do Eswatini and Myanmar rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Eswatini ranks 25th and Myanmar ranks 24th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.